Testing of a System for Remote Ischemic Conditioning in Cerebral Small Vessel Disease and Pre-hospital Stroke Care
Condition(s) studied
Investigational drug(s) / intervention(s)
Remote ischemic conditioning (RIC) progammable device: RIC induces brief periods of ischemia-reperfusion in a limb. In our study, this is accomplished using a new device that can be remotely programmed to deliver either true RIC or a sham protocol, with remote monitoring capabilities to track completion of treatment sessions.
Study summary
This early phase trial will address the following key objectives:
1. Completion of initial safety and tolerability testing of our viable prototype for remote ischemic conditioning (RIC) with patients with (a) CSVD and (b) acute ischemic stroke.
2. Usability testing of the prototype with patients and healthcare professionals, with further optimization.
Approximately 24 patients with CSVD will be recruited to use the RIC device daily for 60 days and provide feedback. They will be randomized in a 1:1 ratio to either true RIC therapy or sham control for the first 30 days, after which the sham group will cross over to receive true RIC for the remaining 30 days.
Feasibility testing will be done in the mobile stroke unit on up to 10 patients with acute ischemic stroke.
An additional 10 stroke physicians and paramedics will conduct device usability testing and provide feedback.
Eligibility
Primary outcome measure(s)
- Treatment adherence or completion — 60 days of daily sessions for patients with CSVD, 6 cycles (each cycle length: 10 minutes) for MSU-based patients with stroke
Proportion of total planned sessions completed. Successful adherence will be defined as completing ≥80% of sessions.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Foothills Medical Centre | Calgary | Alberta |
More University of Calgary trials in Canada
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05967728 on ClinicalTrials.gov ↗ ← All trials in Canada